© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Judd W. Moul, MD, FACS, provides insight on screening and diagnosis of prostate cancer, and comments on the use of biomarker tests to aid in risk stratification, management, and treatment.
April 25th 2022
Judd W. Moul, MD, FACS, introduces the patient profile and discusses typical characteristics of patients undergoing prostate cancer screening in his practice.
A commentary on increasing trends in prostate cancer incidence and how many patients typically present with severe disease.
Judd W. Moul, MD, FACS, reviews challenges of early detection of prostate cancer, and strategies to mitigate them.
A focused discussion on the use of tools such as digital rectal exam, prostate biopsy, and MRI in prostate cancer diagnosis, staging, and grading.
Judd W. Moul, MD, FACS, introduces available blood- and urine-based biomarker tests for prostate cancer screening, and discusses how they might overcome limitations of commonly used modalities.
Judd W. Moul, MD, FACS, provides insight into the timing of biomarker testing in the prostate cancer screening process, and discusses which patients might benefit the most from testing.
An overview of the clinical validity and utility of a urine-based, exosomal molecular test for prostate cancer screening and risk assessment.
Judd W. Moul, MD, FACS, gives a real-world overview of how the exosome-based test is used in clinical practice.
An expert urologic oncologist revisits a patient profile and discusses how he would have approached the patient’s prostate cancer screening process.
Judd W. Moul, MD, FACS, wraps up by discussing remaining unmet needs and potential future improvements in imaging modalities for prostate cancer screening.